Functional MRI for anticancer therapy assessment

European Journal of Cancer

Volumn 38, Issue 16, 2002, Pages 2116-2127

  Padhani, A R ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Magnetic resonance imaging; Treatment response; Tumour

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; VASCULOTROPIN;

CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DISTRIBUTION; DRUG TRANSPORT; EXTRACELLULAR SPACE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MICROVASCULATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME; ULTRASOUND;

EID: 0036840665     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00388-X     Document Type: Article

References (109)

1. Miller A.et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
2. WHO WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 48. 1979;World Health Organization, Geneva, Switzerland.
3. Hawthorn J. A Practical Guide to EORTC Studies. 1994;European Organisation for the Research and Treatment of Cancer (EORTC), Brussels.
4. Therasse P.et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92:2000;205-216.
5. Thiesse P.et al. Response rate accuracy in oncology trials. reasons for interobserver variability. Groupe Francais d'Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer J. Clin. Oncol. 15:1997;3507-3514.
6. Smith T.A. FDG uptake, tumour characteristics and response to therapy. a review Nucl. Med. Commun. 19:1998;97-105.
7. Hoekstra O.S.et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J. Nucl. Med. 34:1993;1706-1710.
8. Husband J.E., Hawkes D.J., Peckham M.J. CT estimations of mean attenuation values and volume in testicular tumours. a comparison with surgical and histologic findings Radiology. 144:1982;553-558.
9. Weissleder R. Molecular imaging exploring the next frontier. Radiology. 212:1999;609-614.
10. Folkman J. The role of angiogenesis in tumour growth. Semin. Cancer Biol. 3:1992;65-71.
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31.
12. Brown J.M., Giaccia A.J. The unique physiology of solid tumors. opportunities (and problems) for cancer therapy Cancer Res. 58:1998;1408-1416.
13. Tomida A., Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des. 14:1999;169-177.
14. Wells P., Harte R.J.A., Price P. Positron emission tomography. a new investigational area for cancer research Clin. Oncol. 8:1996;7-14.
15. Robinson S.P., Barton S.J., McSheehy P.M., Griffiths J.R. Nuclear magnetic resonance spectroscopy of cancer. Br. J. Radiol. 70:1997;S60-S69.
16. Padhani A.R., Husband J.E. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin. Radiol. 56:2001;607-620.
17. Chenevert T.L., Stegman L.D., Taylor J.M.et al. Diffusion magnetic resonance imaging. an early surrogate marker of therapeutic efficacy in brain tumours J. Natl. Cancer Inst. 92:2000;2029-2036.
18. Koh W.J.et al. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;199-212.
19. Weissleder R., Mahmood U. Molecular imaging. Radiology. 219:2001;316-333.
20. Sipkins D.A., Cheresh D.A., Kazemi M.R., Nevin L.M., Bednarski M.D., Li K.C. Detection of tumour angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat. Med. 4:1998;623-626.
21. Nevi D., Carnemolla B., Nissim A.et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol. 15:1997;1271-1275.
22. Bredow S., Lewin M., Hoffmann B., Marecos E., Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur. J. Cancer. 36:2000;675-681.
23. Abramovitch R., Dafni H., Smouha E.et al. In vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal. magnetic resonance imaging of C6 rat glioma in nude mice Cancer Res. 59:1999;5012-5016.
24. Blankenberg F.G., Katsikis P.D., Tait J.F.et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci. USA. 95:1998;6349-6354.
25. Neeman M., Provenzale J.M., Dewhirst M.W. Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. Semin. Radiat. Oncol. 1:2001;70-82.
26. Brasch R.C., Li K.C., Husband J.E.et al. In vivo monitoring of tumor angiogenesis with MR imaging. Acad. Radiol. 7:2000;812-823.
27. Blankenberg F.G., Eckelman W.C., Strauss H.W.et al. Role of radionuclide imaging in trials of antiangiogenic therapy. Acad. Radiol. 7:2000;851-867.
28. Miles K.A., Charnsangavej C., Lee F.T., Fishman E.K., Horton K., Lee T.Y. Application of CT in the investigation of angiogenesis in oncology. Acad. Radiol. 7:2000;840-850.
29. Ferrara K.W., Merritt C.R., Burns P.N., Foster F.S., Mattrey R.F., Wickline S.A. Evaluation of tumor angiogenesis with US. imaging, Doppler, and contrast agents Acad. Radiol. 7:2000;824-839.
30. Yuh W.T. An exciting and challenging role for the advanced contrast MR imaging. J. Magn. Reson. Imaging. 10:1999;221-222.
31. Taylor J.S., Tofts P.S., Port R.et al. MR imaging of tumor microcirculation. promise for the new millennium J. Magn. Reson. Imaging. 10:1999;903-907.
32. Zierler K.L. Theory of use of indicators to measure blood flow and extracellular volume and calculation of trans capillary movement of tracers. Circulation Res. 12:1963;464-471.
33. Crone C. The permeability of capillaries in various organs as determined by the use of indicator diffusion' method. Acta Physiol. Scand. 58:1963;292-305.
34. Kety S.S. The theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol. Rev. 3:1951;1-41.
35. Rosen B.R., Belliveau J.W., Aronen H.J.et al. Susceptibility contrast imaging of cerebral blood volume. human experience Magn. Reson. Med. 22:1991;293-299.
36. Edelman R.R., Mattle H.P., Atkinson D.J.et al. Cerebral blood flow. assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T Radiology. 176:1990;211-220.
37. Dennie J., Mandeville J.B., Boxerman J.L., Packard S.D., Rosen B.R., Weisskoff R.M. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn. Reson. Med. 40:1998;793-799.
38. Bruening R., Berchtenbreiter C., Holzknecht N.et al. Effects of three different doses of a bolus injection of gadodiamide. assessment of regional cerebral blood volume maps in a blinded reader study Am. J. Neuroradiol. 21:2000;1603-1610.
39. Sorensen A.G., Tievsky A.L., Ostergaard L., Weisskoff R.M., Rosen B.R. Contrast agents in functional MR imaging. J. Magn. Reson. Imaging. 7:1997;47-55.
40. Rempp K.A., Brix G., Wenz F., Becker C.R., Guckel F., Lorenz W.J. Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. Radiology. 193:1994;637-641.
41. Wenz F., Rempp K., Hess T.et al. Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue. quantification with dynamic susceptibility contrast MR imaging Am. J. Roentgenol. 166:1996;187-193.
42. Moseley M.E., Vexler Z., Asgari H.S.et al. Comparison of Gd- and Dy-chelates for T2 contrast-enhanced imaging. Magn. Reson. Med. 22:1991;259-264.
43. Lev M.H., Kulke S.F., Sorensen A.G.et al. Contrast-to-noise ratio in functional MRI of relative cerebral blood volume with sprodiamide injection. J. Magn. Reson. Imaging. 7:1997;523-527.
44. Ichikawa T., Haradome H., Hachiya J., Nitatori T., Araki T. Characterisation of hepatic lesions by perfusion-weighted MR imaging with an echoplanar sequence. Am. J. Roentgenol. 170:1998;1029-1034.
45. Kuhl C.K., Bieling H., Gieseke J.et al. Breast neoplasms. T2* susceptibility-contrast, first-pass perfusion MR imaging Radiology. 202:1997;87-95.
46. Kvistad K.A., Lundgren S., Fjosne H.E., Smenes E., Smethurst H.B., Haraldseth O. Differentiating benign and malignant breast lesions with T2*-weighted first pass perfusion imaging. Acta Radiol. 40:1999;45-51.
47. Aronen H.J., Gazit I.E., Louis D.N.et al. Cerebral blood volume maps of gliomas. comparison with tumour grade and histologic findings Radiology. 191:1994;41-51.
48. Sugahara T., Korogi Y., Kochi M.et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. Am. J. Roentgenol. 171:1998;1479-1486.
49. Aronen H.J., Glass J., Pardo F.S.et al. Echo-planar MR cerebral blood volume mapping of gliomas. Clinical utility. Acta Radiol. 36:1995;520-528.
50. Knopp E.A., Cha S., Johnson G.et al. Glial neoplasms. dynamic contrast-enhanced T2*-weighted MR imaging Radiology. 211:1999;791-798.
51. Bagley L.J., Grossman R.I., Judy K.D.et al. Gliomas. correlation of magnetic susceptibility artifact with histologic grade Radiology. 202:1997;511-516.
52. Cha S., Knopp E.A., Johnson G.et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carbolatin. Am. J. Neuroradiol. 21:2000;881-890.
53. Roberts T.P. Physiologic measurements by contrast-enhanced MR imaging. expectations and limitations J. Magn. Reson. Imaging. 7:1997;82-90.
54. Evelhoch J.L. Key factors in the acquisition of contrast kinetic data for oncology. J. Magn. Reson. Imaging. 10:1999;254-259.
55. Parker G.J.M., Suckling J., Tanner S.F.et al. Probing tumor microvessel density by measurement, analysis and display of contrast agent uptake kinetics. J. Magn. Reson. Imaging. 7:1997;564-574.
56. Flickinger F.W., Allison J.D., Sherry R.M., Wright J.C. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn. Reson. Imaging. 11:1993;617-620.
57. Kaiser W.A., Zeitler E. MR imaging of the breast. fast imaging sequences with and without Gd-DTPA - preliminary observations Radiology. 170:1989;681-686.
58. Gribbestad I.S., Nilsen G., Fjosne H.E., Kvinnsland S., Haugen O.A., Rinck P.A. Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography. J. Magn. Reson. Imaging. 4:1994;477-480.
59. Hoffmann U., Brix G., Knopp M.V., Hess T., Lorenz W.J. Pharmacokinetic mapping of the breast. a new method for dynamic MR mammography Magn. Reson. Med. 33:1995;506-514.
60. Parker G.M., Baustert I., Tanner S.F., Leach M.O. Improving image quality and T1 measurements using saturation recovery TurboFLASH with approximate K-space normalisation filter. Magn. Reson. Imaging. 18:2000;157-167.
61. Tofts P.S. Modelling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging. 7:1997;91-101.
62. Tofts P.S., Brix G., Buckley D.L.et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer. standardized quantities and symbols J. Magn. Reson. Imaging. 10:1999;223-232.
63. Tofts P.S., Berkowitz B., Schnall M.D. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn. Reson. Med. 33:1995;564-568.
64. Stomper P.C., Winston J.S., Herman S., Klippenstein D.L., Arredondo M.A., Blumenson L.E. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res. Treat. 45:1997;39-46.
65. Hawighorst H., Knapstein P.G., Weikel W.et al. Angiogenesis of uterine cervical carcinoma. characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement Cancer Res. 57:1997;4777-4786.
66. Tynninen O., Aronen H.J., Ruhala M.et al. MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest. Radiol. 34:1999;427-434.
67. Buckley D.L., Drew P.J., Mussurakis S., Monson J.R., Horsman A. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J. Magn. Reson. Imaging. 7:1997;461-464.
68. Hulka C.A., Edmister W.B., Smith B.L.et al. Dynamic echo-planar imaging of the breast. experience in diagnosing breast carcinoma and correlation with tumor angiogenesis Radiology. 205:1997;837-842.
69. Cooper R.A., Carrington B.M., Loncaster J.A.et al. Tumor oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Rad. Oncol. 57:2000;53-59.
70. Knopp M.V., Weiss E., Sinn H.P.et al. Pathophysiologic basis of contrast enhancement in breast tumours. J. Magn. Reson. Imaging. 10:1999;260-266.
71. Furman-Haran E., Margalit R., Grobgeld D., Degani H. Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. Proc. Natl. Acad. Sci. USA. 93:1996;6247-6251.
72. Bhujwalla Z.M., Artemov D., Natarajan K., Ackerstaff E., Solaiyappam M. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia. 3:2001;143-153.
73. George ML, Dzik-Jurasz ASK, Padhani AR, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br. J. Surg [in press].
74. Pham C.D., Roberts T.P., van Bruggen N.et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest. 16:1998;225-230.
75. Thomas A., Morgan B., Drevs J.et al. Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;A279.
76. Matsubayashi R., Matsuo Y., Edakuni G., Satoh T., Tokunaga O., Kudo S. Breast masses with peripheral rim enhancement on dymanic contrast-enhanced MR images. correlation of MR findings with histologic features and expression of growth factors Radiology. 217:2000;841-848.
77. Yamashita Y., Baba T., Baba Y.et al. Dymanic contrast-enhanced MR imaging of uterine cervical cancer. pharmacokinetic analysis with histopathologis correlation and its importance in predicting the outcome of radiation therapy Radiology. 216:2000;803-809.
78. Roberts H.C., Roberts T.P., Brasch R.C., Dillon W.P. Quantitative measurement of microvascular permeability in human brain tumours achieved using dynamic contrast-enhanced MR imaging. correlation with histologic grade Am. J. Neuroradiol. 21:2000;891-899.
79. Verstraete K.L., De Deene Y., Roels H., Dierick A., Uyttendaele D., Kunnen M. Benign and malignant musculoskeletal lesions. dynamic contrast-enhanced MR imaging-parametric "first-pass" images depict tissue vascularization and perfusion Radiology. 192:1994;835-843.
80. Liu P.F., Krestin G.P., Huch R.A.et al. MRI of the uterus, uterine cervix, and vagina. diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging Eur. Radiol. 8:1998;433-1440.
81. Barentsz J.O., Jager G.J., van Vierzen P.B.et al. Staging urinary bladder cancer after transurethral biopsy. value of fast dynamic contrast-enhanced MR imaging Radiology. 201:1996;185-193.
82. Hawighorst H., Weikel W., Knapstein P.G.et al. Angiogenic activity of cervical carcinoma. assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome Clin. Cancer Res. 4:1998;2305-2312.
83. Mayr N.A., Yuh W.T., Magnotta V.A.et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer. a new noninvasive predictive assay Int. J. Radiat. Oncol. Biol. Phys. 36:1996;623-633.
84. Dao T.H., Rahmouni A., Campana F., Laurent M., Asselain B., Fourquet A. Tumour recurrence versus fibrosis in the irradiated breast. differentiation with dynamic gadolinium-enhanced MR imaging Radiology. 187:1993;751-755.
85. Heywang-Kobrunner S.H., Schlegel A., Beck R.et al. Contrast-enhanced MRI of the breast after limited surgery and radiation therapy. J. Comput. Assist. Tomogr. 17:1993;891-900.
86. Kinkel K., Tardivon A.A., Soyer P.et al. Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm. A prospective study of 41 patients. Radiology. 200:1996;453-458.
87. Hawnaur J.M., Zhu X.P., Hutchinson C.E. Quantitative dynamic contrast enhanced MRI of recurrent pelvic masses in patients treated for cancer. Br. J. Radiol. 71:1998;1136-1142.
88. Blomqvist L., Fransson P., Hindmarsh T. The pelvis after surgery and radio-chemotherapy for rectal cancer studied with Gd-DTPA-enhanced fast dynamic MR imaging. Eur. Radiol. 8:1998;781-787.
89. Reddick W.E., Taylor J.S., Fletcher B.D. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J. Magn. Reson. Imaging. 10:1999;277-285.
90. van der Woude H.J., Bloem J.L., Verstraete K.L., Taminiau A.H., Nooy M.A., Hogendoorn P.C. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy. value of dynamic MR imaging in detecting viable tumor before surgery Am. J. Roentgenol. 165:1995;593-598.
91. Knopp M.V., Brix G., Junkermann H.J., Sinn H.P. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn. Reson. Imaging Clin. N. Am. 2:1994;633-658.
92. Barentsz J.O., Berger-Hartog O., Witjes J.A.et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology. 207:1998;791-797.
93. Padhani AR, Hayes C, Assersohn L, Powles T, Leach MO, Husband JE. Response of breast carcinoma to chemotherapy - MR permeability changes using histogram analysis. Proc. Soc. Magn. Reson. Med. 8th Scientific Meeting, Colorado, 2000.
94. de Vries A., Griebel J., Kremser C.et al. Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma. preliminary results and implications for therapy Radiology. 217:2000;385-391.
95. Mayr N.A., Yuh W.T., Arnholt J.C.et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J. Magn. Reson. Imaging. 12:2000;1027-1033.
96. Padhani A.R., MacVicar A.D., Gapinski C.J.et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology. 218:2001;365-374.
97. Li W., Brophy D.P., Chen Q.et al. Semiquantitative assessment of uterine perfusion using first pass dynamic contrast-enhanced MR imaging for patients treated with uterine fibroid embolization. J. Magn. Reson. Imaging. 12:2000;1004-1008.
98. Padhani A.R., O'Donell A., Hayes C.et al. Dynamic contrast enhanced MR imaging in the evaluation of antiangiogenesis therapy. Molecular targets and cancer therapeutics. discovery, development and cancer therapeutics. The Joint AACR-NCI-EORTC Meeting, Washington 1999 Clin. Cancer Res. 5:1999;3828S.
99. Galbraith S.M., Lodge M., Taylor N.J.et al. Combretastatin A4 phosphate reduces tumour blood flow in animal and man, demonstrated by MRI. Proc. Am. Soc. Clin. Oncol. 20:2001;A279.
100. Brasch R., Pham C., Shames D.et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J. Magn. Reson. Imaging. 7:1997;68-74.
101. Gerlowski L.E., Jain R.K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31:1986;288-305.
102. Jain R. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6:1987;559-593.
103. van Dijke C., Brasch R., Roberts T.et al. Mammary carcinoma model. correlation of macromolecular contrast enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density Radiology. 198:1996;813-818.
104. Turetschek K., Huber S., Floyd E.et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology. 218:2001;562-569.
105. Ogawa S., Menon R.S., Kim S.G.et al. On the characteristics of functional magnetic resonance imaging of the brain. Annu. Rev. Biophys. Biomol. Struct. 27:1998;447-474.
106. Abramovitch R., Frenkiel D., Neeman M. Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging. Magn. Reson. Med. 39:1998;813-824.
107. van Zijl P.C., Eleff S.M., Ulatowski J.A.et al. Quantitative assessment of blood flow, blood volume and blood oxygenation effects in functional magnetic resonance imaging. Nat. Med. 4:1998;159-167.
108. Robinson S.P., Collingridge D.R., Howe F.A., Rodrigues L.M., Chaplin D.J., Griffiths J.R. Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed. 12:1999;98-106.
109. Taylor N.J., Baddeley H., Goodchild H.et al. BOLD MRI of huam tumour oxygenation during carbogen breathing. J. Magn. Reson. Imaging. 14:2001;156-163.